Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: A co-registered SPECT and MRI study

Psychiatry Research - Neuroimaging

Volumn 98, Issue 1, 2000, Pages 15-28

  Chang, Linda ^a   Grob, Charles S ^a   Ernst, Thomas ^a   Itti, Laurent ^a   Mishkin, Fred S ^a   Jose Melchor, Rosemarie ^a   Poland, Russell E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Magnetic resonance imaging; Serotonin; Single photon emission computed tomography; Substance abuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VISUAL CORTEX;

ADULT; BRAIN; CASE-CONTROL STUDIES; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RADIOPHARMACEUTICALS; SEROTONIN AGENTS; TECHNETIUM TC 99M EXAMETAZIME; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034723753     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(99)00048-7     Document Type: Article

References (38)

1. Ali S.F., Newport G.D., Scallet A.C., Binienda Z., Ferguson S.A., Bailey J.R., Paule M.G., Slikker W.J. Oral administration of MDMA produces selective 5-HT depletion in the non-human primate. Neurotoxicology and Teratology. 15:1993;91-96.
2. Battaglia G., Yeh S.Y., DeSouza E.B. MDMA-induced neurotoxicity parameters of degeneration and recovery of brain serotonin systems. Pharmacology, Biochemistry and Behavior. 29:1988;269-274.
3. Baumgarten H.G., Zimmerman B. Selective Neurotoxicity. 1992;Springer-Verlag, Berlin.
4. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA (ecstasy) users. Neurology. 51:1998;1532-1537.
5. 1H MRS abnormalities in 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) users. Journal of Magnetic Resonance Imaging. 10:1999;521-526.
6. Cohen Z., Bonvento G., Lacombe P., Hamel E. Serotonin in the regulation of brain microcirculation. Progress in Neurobiology. 50:1996;335-362.
7. Colado M.I., Green A.R. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurons using chlormethiazole, dizocilpine and other protective compounds. British Journal of Pharmacology. 111:1994;131-136.
8. Fisher C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Journal of Neuroscience. 15:1995;5476-5485.
9. Fozard, J.R., 1989. 5-HT in migraine: evidence in 5-HT receptor antagonists for a neuronal actiology. In: Sandler, M., Collins, G. (Eds.), Migraine, a Spectrum of Ideas. Oxford University Press, pp. 124-141.
10. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'). Psychopharmacology. 119:1995;247-260.
11. Grob C.S., Poland R.E., Chang L., Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behavioural Brain Research. 73:1996;103-107.
12. Ingvar M., Lindvall O., Stenevi U. Apomorphine-induced changes in local cerebral blood flow in normal rats and after lesions of the dopaminergic nigrostriatal bundle. Brain Research. 262:1983;259-265.
13. Itti L., Chang L., Ernst T., Mishkin F. Improved 3-D correction for partial volume effects in brain SPECT. Human Brain Mapping. 5:1997;379-388.
14. Itti L., Chang L., Mangin J.F., Darcourt J., Ernst T. Robust multimodality registration for brain mapping. Human Brain Mapping. 5:1997;3-17.
15. Johnson M.P., Huang X., Nichols D.E. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a non-neurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacology, Biochemistry and Behavior. 40:1991;915-922.
16. Kahn D.A., Prohovnik I., Lucas L.R., Sackeim H.A. Dissociated effects of amphetamine on arousal and cortical blood flow in humans. Biological Psychiatry. 25:1989;755-767.
17. m-HMPAO brain SPECT. Nuclear Medicine Communications. 15:1994;94-98.
18. 2O PET study in humans. Neuroscience Letters. 176:1994;21-24.
19. Lew R., Sabol K.E., Chou C., Vosmer G.L., Richards J., Seider L.S. MDMA-induced serotonin deficits are followed by partial recovery over a 52-week period. II. Radioligand binding and autoradiography studies. Journal of Pharmacology and Experimental Therapeutics. 276:1996;855-865.
20. Lewis L.A., Rose M.W. The gay dance party culture in Sydney: a qualitative analysis. Journal of Homosexuality. 29:1995;41-70.
21. McBean D.E., Sharkey J., Ritchie I.M., Kelly P.A.T. Evidence for a possible role for serotonergic systems in the control of cerebral blood flow. Brain Research. 537:1990;307-310.
22. McBean D.E., Sharkey J., Ritchie I.M., Kelly P.A.T. Cerebrovascular and functional consequences of 5-HTIA receptor activation. Brain Research. 555:1991;159-163.
23. McCann U.D., Ridenour B.S., Shaham Y., Ricaurte G.A. 5-HT neurotoxicity after MDMA: a controlled study in humans. Neuropsychopharmocology. 10:1994;129-138.
24. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurons in human beings. The Lancet. 352:1998;1433-1437.
25. Molliver M.E. Serotonergic neuronal systems: what their anatomic organization tells us about function. Journal of Clinical Psychopharmocology. 7:1987;3S-S23.
26. Payne J.K., Trivedi M.H., Devous M.D.S. Comparison of technetium-99m-HMPAO and xenon-133 measurements of regional cerebral blood flow by SPECT. Journal of Nuclear Medicine. 37:1996;1735-1740.
27. Peroutka S.J. Incidence of recreational use of 3,4-methylendioxymethamphetamine (MDMA, 'ecstasy') on an undergraduate campus. New England Journal of Medicine. 317:1987;1542-1543.
28. Ricaurte G.A., DeLanney L.E., Irwin I., Langston J.W. Toxic effects of MDMA on 5-HT neurons in primate: importance of route and frequency of administration. Brain Research. 446:1988;165-168.
29. Ricaurte G.A., Finnegan K.T., Irwin I., Langston J.W. Aminergic metabolites in CSF of humans previously exposed to MDMA: preliminary observations. Annals of the New York Academy of Sciences. 600:1993;699-700.
30. Ricaurte G.A., Martello A.L., Katz J.L., Martello M.B. Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. Journal of Pharmacology and Experimental Therapeutics. 261:1992;616-622.
31. Sabol K.E., Lew R., Richards J.B., Vosmer G.L., Seiden L.S. MDMA-induced serotonin deficits are followed by partial recovery over a 52-week period. I. Synaptosomal uptake and tissue concentrations. Journal of Pharmacology and Experimental Therapeutics. 276:1996;846-854.
32. Scanzello C.R., Hatzidimitriou G., Martello A.L., Katz J.L., Ricaurte G.A. Serotonergic recovery after (±)3,4-methylenedioxymethamphetamine injury: observations in rats. Journal of Pharmacology and Experimental Therapeutics. 264:1993;1484-1491.
33. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics. 240:1987;1-7.
34. Sharma H.S., Olsson Y., Dey P.K. Changes in blood-brain barrier and cerebral blood flow following elevation of circulating serotonin level in anesthetized rats. Brain Research. 517:1990;215-223.
35. Shulgin, A.T., Nichols, D.E. (Eds), 1978. Characterization of Three New Psychotomimetics. The Psychopharmacology of Hallucinogens. Pergamon Press, New York.
36. Underwood M.D., Bakalian M.J., Arango V., Smith R.W., Mann J.J. Regulation of cortical blood flow by the dorsal raphe nucleus: topographic organization of cerebrovascular regulatory regions. Journal of Cerebral Blood Flow and Metabolism. 12:1992;664-673.
37. Volkow N.D., Fowler J.S., Wolf A.P., Hitzemann R., Dewey S., Bendriem B., Alpert R., Hoff A. Changes in brain glucose metabolism in cocaine dependence and withdrawal. American Journal of Psychiatry. 148:1991;621-626.
38. Wang G.J., Volkow N.D., Fowler J.S., Ferrieri R., Schleyer D.J., Alexoff D., Pappas N., Lieberman J., King P., Warner D., Wong C., Hitzemann R.J., Wolf A.P. Methylphenidate decreases regional cerebral blood flow in normal human subjects. Life Sciences. 54:1994;143-146.